NASDAQ:SUPNSupernus Pharmaceuticals Stock Price, Forecast & News

Supernus Pharmaceuticals' stock was trading at $16.15 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SUPN shares have increased by 51.7% and is now trading at $24.50. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Supernus Pharmaceuticals in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Supernus Pharmaceuticals.

Supernus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Supernus Pharmaceuticals.

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) posted its quarterly earnings data on Tuesday, May, 5th. The specialty pharmaceutical company reported $0.40 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.30 by $0.10. The specialty pharmaceutical company earned $94.98 million during the quarter, compared to the consensus estimate of $84.01 million. Supernus Pharmaceuticals had a net margin of 28.90% and a return on equity of 20.31%. The firm's quarterly revenue was up 11.1% compared to the same quarter last year. During the same quarter last year, the firm posted $0.34 EPS. View Supernus Pharmaceuticals' earnings history.

6 brokers have issued 12-month price targets for Supernus Pharmaceuticals' stock. Their forecasts range from $23.00 to $50.00. On average, they anticipate Supernus Pharmaceuticals' share price to reach $30.50 in the next twelve months. This suggests a possible upside of 24.5% from the stock's current price. View analysts' price targets for Supernus Pharmaceuticals.

News stories about SUPN stock have trended extremely positive recently, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Supernus Pharmaceuticals earned a news impact score of 4.7 on InfoTrie's scale. They also assigned press coverage about the specialty pharmaceutical company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term. View the latest news aboutSupernus Pharmaceuticals.

Supernus Pharmaceuticals saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 3,960,000 shares, a drop of 10.6% from the April 30th total of 4,430,000 shares. Based on an average daily trading volume, of 684,000 shares, the short-interest ratio is presently 5.8 days. Currently, 7.8% of the shares of the stock are short sold. View Supernus Pharmaceuticals' Current Options Chain.

Some companies that are related to Supernus Pharmaceuticals include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Allergan (AGN), Zoetis (ZTS), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX) and Corcept Therapeutics (CORT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Supernus Pharmaceuticals investors own include NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), AbbVie (ABBV), GW Pharmaceuticals PLC- (GWPH), Pfizer (PFE), Exelixis (EXEL), Netflix (NFLX), Cara Therapeutics (CARA) and Corcept Therapeutics (CORT).

Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol "SUPN."

Supernus Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Morgan Stanley (2.17%), Morgan Stanley (2.17%), Rice Hall James & Associates LLC (1.80%), Geode Capital Management LLC (1.44%), Aristotle Capital Boston LLC (1.41%) and Ashford Capital Management Inc. (1.10%). Company insiders that own Supernus Pharmaceuticals stock include Gregory S Patrick, Jack A Khattar, Padmanabh P Bhatt and Stefan KF Schwabe. View institutional ownership trends for Supernus Pharmaceuticals.

SUPN stock was sold by a variety of institutional investors in the last quarter, including Mackay Shields LLC, Wells Fargo & Company MN, Loomis Sayles & Co. L P, Deutsche Bank AG, Ashford Capital Management Inc., Aequim Alternative Investments LP, Mutual of America Capital Management LLC, and State Board of Administration of Florida Retirement System. View insider buying and selling activity for Supernus Pharmaceuticals.

SUPN stock was purchased by a variety of institutional investors in the last quarter, including Matarin Capital Management LLC, Two Sigma Advisers LP, Two Sigma Investments LP, Morgan Stanley, Morgan Stanley, Voloridge Investment Management LLC, Pictet Asset Management Ltd., and S&T Bank PA. View insider buying and selling activity for Supernus Pharmaceuticals.

Shares of SUPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of SUPN stock can currently be purchased for approximately $24.50.

Supernus Pharmaceuticals has a market capitalization of $1.29 billion and generates $392.76 million in revenue each year. The specialty pharmaceutical company earns $113.06 million in net income (profit) each year or $2.10 on an earnings per share basis. Supernus Pharmaceuticals employs 448 workers across the globe.

The official website for Supernus Pharmaceuticals is www.supernus.com.

Supernus Pharmaceuticals' mailing address is 1550 E GUDE DR, ROCKVILLE MD, 20850. The specialty pharmaceutical company can be reached via phone at 301-838-2500 or via email at [email protected]